Publications

The Lancet. Oncology

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

01-01-2020

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

European urology

Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.

01-12-2019

The American journal of surgical pathology

Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.

01-12-2019

Nature communications

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

20-11-2019

Nature medicine

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

01-11-2019

Cancer research

Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC.

01-11-2019

Genome medicine

Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.

17-10-2019

European urology focus

Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immunogram.

01-09-2019

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.

01-09-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

15-08-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

01-07-2019

Cancers

Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients.

25-04-2019

Cancers

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.

29-03-2019

International journal of cancer

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

15-03-2019

The Journal of urology

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

01-03-2019

European urology

Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8].

01-03-2019

European urology

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

01-03-2019

Science translational medicine

Enhanced detection of circulating tumor DNA by fragment size analysis.

07-11-2018

International journal of cancer

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

01-10-2018

Urologic oncology

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

01-09-2018

Urologic oncology

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

01-07-2018

Oncotarget

Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma.

06-04-2018

European urology

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

01-03-2018

Lancet (London, England)

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

24-02-2018

Nature

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

22-02-2018

European urology

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

01-02-2018

Lancet (London, England)

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

18-11-2017

European urology

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

01-10-2017

International urology and nephrology

FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.

01-09-2017

Scientific reports

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

17-07-2017

European urology

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

01-06-2017

Lancet (London, England)

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

07-01-2017

European journal of cancer (Oxford, England : 1990)

Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.

01-12-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

01-11-2016

Urologic oncology

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

01-10-2016

Bladder cancer (Amsterdam, Netherlands)

Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer.

27-07-2016

Annals of oncology : official journal of the European Society for Medical Oncology

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

01-07-2016

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Treatment outcome of supraglottoplasty vs. wait-and-see policy in patients with laryngomalacia.

01-06-2016

Lancet (London, England)

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

07-05-2016

European urology

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

01-03-2016

European journal of cancer (Oxford, England : 1990)

Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.

01-02-2016

World journal of urology

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

01-02-2016

European urology

Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

01-08-2015

European urology

The molecular background of urothelial cancer: ready for action?

01-02-2015

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

[Not Available].

01-11-2014

BJU international

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

01-07-2014

BMC cancer

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.

01-12-2013

Clinical cancer research : an official journal of the American Association for Cancer Research

Inhibition of the PI3K pathway: hope we can believe in?

15-06-2010